{"title":"Pharmacokinetic/Pharmacodynamic Analysis the Probability of Target Attainment of Posaconazole against Mucorales Species in Patients with Mucormycosis","authors":"Ying Wang, Jingyi Zhao, Yinhui Yao, Junhui Hu, Jiuli Hu, Xun Xiao, Yanwu Zhao","doi":"10.4236/pp.2020.115007","DOIUrl":null,"url":null,"abstract":"The objective of this study was to investigate the probability \nof target attainment of various posaconazole \ndosing regimens against Mucorales species in patients with mucormycosis. \nAccording to pharmacokinetic/pharmacodynamic parameters of posaconazole in \nadults, the dosage regimen of posaconazole for mucormycosis included 50, 100, 200 and 400 mg orally \nq12h. Monte Carlo Simulation \nanalysed the published parameters of pharmacokinetics and the MIC values of \nmucormycosis in Mucorales species. The results showed that posaconazole did not affect Rhizopus arrhizus and Mucor sp. The optimal dosage of \nposaconazole for Rhizopus microsporus and Rhizomucor pusillus was 400 mg orally q12h and the best dosage regimen for Lichtheimia corymbifera was 200 mg orally \nq12h. The antifungal activity of posaconazole against mucormycosis was different, and the dosage regimen needs to \nadjust according to fungal species.","PeriodicalId":20031,"journal":{"name":"Pharmacology & Pharmacy","volume":"77 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacology & Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4236/pp.2020.115007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
The objective of this study was to investigate the probability
of target attainment of various posaconazole
dosing regimens against Mucorales species in patients with mucormycosis.
According to pharmacokinetic/pharmacodynamic parameters of posaconazole in
adults, the dosage regimen of posaconazole for mucormycosis included 50, 100, 200 and 400 mg orally
q12h. Monte Carlo Simulation
analysed the published parameters of pharmacokinetics and the MIC values of
mucormycosis in Mucorales species. The results showed that posaconazole did not affect Rhizopus arrhizus and Mucor sp. The optimal dosage of
posaconazole for Rhizopus microsporus and Rhizomucor pusillus was 400 mg orally q12h and the best dosage regimen for Lichtheimia corymbifera was 200 mg orally
q12h. The antifungal activity of posaconazole against mucormycosis was different, and the dosage regimen needs to
adjust according to fungal species.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
